Merus N.V.: Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma
This marks the second BTD for petosemtamab in HNSCCUTRECHT, The Netherlands and CAMBRIDGE, Mass., Feb. 18, 2025(Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length mult ...
Architecture and Design20hOpinion
Contributing to a sustainable future with TRUECORE® steel light gauge steel framing
In response to global material shortages, rising labour costs, housing affordability challenges, and the increasing impact of ...
Ultragenyx’s BLA for UX111 accepted by FDA for priority review
Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...